Results 181 to 190 of about 11,471 (261)

Amylo Glucosidase

open access: yesThe Journal of the Society of Chemical Industry, Japan, 1964
openaire   +2 more sources

Objective sleep parameters and diurnal blood pressure in concurrent hypertension and type 2 diabetes

open access: yesSleep Research, Volume 3, Issue 3, Page 195-203, September 2026.
Abstract Background Hypertension is a primary cardiovascular complication in type 2 diabetes associated with increased morbidity and mortality. Ambulatory blood pressure monitoring (ABPM) is essential for capturing circadian BP variation, which is closely influenced by sleep. Methods Twenty patients (63.75 ± 4.44 years old, 40% female, duration of T2D:
Yan Zhao   +6 more
wiley   +1 more source

Comparison of active site mutations at subsite + 2 of Anoxybacillus ayderensis A9 β-glucosidase for hydrolysis of pNPG and polydatin. [PDF]

open access: yesBMC Biotechnol
Zada NS   +8 more
europepmc   +1 more source

Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis

open access: yesAndrology, Volume 14, Issue 6, Page 1627-1635, September 2026.
ABSTRACT Background Erectile dysfunction is a prevalent and distressing complication of diabetes mellitus that markedly affects quality of life in male patients. Although the role of diabetes in erectile dysfunction is well‐established, potential drug‐induced sexual dysfunction associated with commonly prescribed antidiabetic medications remains ...
Shan Lin   +3 more
wiley   +1 more source

Systemic medications associate with surgically treated cataract among adults over 50 years in Finland

open access: yesActa Ophthalmologica, Volume 104, Issue 6, Page e630-e647, September 2026.
Abstract Purpose To identify associations between systemic drugs and cataract surgery in Finland. Methods A historic cohort study based on administrative data. Endpoint event was cataract surgery. Use of drugs in question was based on redeemed prescriptions and consisted of 156 drugs.
Antti Riikonen   +3 more
wiley   +1 more source

Simplified Switching to Once‐Weekly Insulin Icodec Without an Initial One‐Time Additional Dose Versus Once‐Daily Insulin Glargine U100 in Basal Insulin‐Treated Type 2 Diabetes (ONWARDS 10): A Randomised Controlled Trial

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7791-7801, September 2026.
ABSTRACT Aims ONWARDS 10 assessed switching from daily basal insulins to once‐weekly insulin icodec without a one‐time additional dose at first injection. Materials and Methods In this treat‐to‐target, open‐label, 26‐week, phase 3b trial, adults with basal‐insulin‐treated type 2 diabetes (T2D) with glycated haemoglobin [HbA1c] 7.0%–10.0% were ...
Julio Rosenstock   +5 more
wiley   +1 more source

EPIC: A Machine-Learning Framework for Product-Dependent Behavior in β‑Glucosidases

open access: yesACS Omega
Ali Malli   +3 more
doaj   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction‐Associated Steatotic Liver Disease

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8277-8287, September 2026.
ABSTRACT Aims Treatment options for metabolic dysfunction‐associated steatotic liver disease (MASLD) are limited. While glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors improve cardiovascular outcomes, comparative effectiveness on liver‐related outcomes remains unclear.
Gregor A. Maier   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy